Oxidation chemistry of (-)-norepinephrine in the presence of L-cysteine

Journal of Medicinal Chemistry

Volumn 39, Issue 10, 1996, Pages 2018-2029

  Shen, Xue Ming ^a   Dryhurst, Glenn ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 S CYSTEINYLNORADRENALIN; 5 S CYSTEINYLNORADRENALIN; 7 (2 AMINO 1 HYDROXYETHYL) 3,4 DIHYDRO 5 HYDROXY 2H 1,4 BENZOTHIAZINE 3 CARBOXYLIC ACID; 8 (2 AMINO 1 HYDROXYETHYL) 3,4 DIHYDRO 5 HYDROXY 2H 1,4 BENZOTHIAZINE 3 CARBOXYLIC ACID; CYSTEINE; MELANIN; NORADRENALIN; NORADRENALIN DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CATECHOLAMINE METABOLISM; CONTROLLED STUDY; CYCLIZATION; DEPIGMENTATION; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; NORADRENERGIC SYSTEM; OXIDATION; PARKINSONISM; PH;

ANIMALS; CYSTEINE; ELECTROCHEMISTRY; MALE; MICE; MICE, INBRED ICR; NOREPINEPHRINE; OXIDATION-REDUCTION; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; THIAZINES;

EID: 0029896774     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960016t     Document Type: Article

References (45)

1. Hornykiewicz, O.; Kish, S. J. Biochemical Pathophysiology of Parkinson's Disease. Adv. Neurol. 1986, 45, 19-34.
2. Hornykiewicz, O. Aging and Neurotoxins as Causitive Factors in Idiopathic Parkinson's Disease - A Critical Analysis of Neurochemical Evidence. Progr. Neuro-Psychopharmacol. Biol. Psychiatry 1989, 13, 319-328.
3. Graham, D. G. Oxidation Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones. Mol. Pharmacol. 1978, 14, 633-643.
4. Rodgers, A. D.; Curzon, G. Melanin Formation by Human Brain In Vitro. J. Neurochem. 1975, 24, 1123-1129.
5. Jenner, P.; Dexter, D. T.; Sian, J.; Schapira, A. H. V.; Marsden, C. D. Oxidative Stress as a Cause of Nigral Cell Death in Parkinson's Disease and Incidental Lewy Body Disease. Ann. Neurol. 1992, 32, S82-S87.
6. Schapira, A. H. V.; Cooper, J. M.; Dexter, D.; Clark, J. B.; Jenner, P.; Marsden, C. D. Mitochondrial Complex I Deficiency in Parkinson's Disease. J. Neurochen. 1990, 54, 823-827.
7. Riederer, P.; Sofic, E.; Rausch, W. D.; Schmidt, B.; Reynolds, G. P.; Jellinger, K.; Youdim, M. B. H. Transition Metals, Ferritin, Glutathione and Ascorbic Acid in Parkinsonian Brains. J. Neurochem. 1989, 52, 515-520.
8. Sofic, E.; Lange, K. W.; Jellinger, K.; Riederer, P. Reduced and Oxidized Glutathione in the Substantia Nigra of Patients with Parkinson's Disease. Neurosci. Lett. 1992, 142, 128-130.
9. Fornstedt, B.; Brun, A.; Rosengren, E.; Carlsson, A. The Apparent Autoxidation Rate of Catechols in Dopamine-Rich Regions of Substantia Nigra. J. Neural Transm. 1989, 1 (P-D Sect.), 279-295.
10. Sian, J.; Dexter, D. T.; Jenner, P.; Marsden, C. D. Glutathione - Related Enzymes in Brain in Basal Ganglia Disorders. Br. J. Pharmacol. (Suppl.) 1992, 107, 429P.
11. Kastner, A.; Hirsch, E. C.; Lejeune, O.; Javoy-Agid, F.; Roscol, O.; Agid, Y. Is the Vulnerbility of Neurons in the Substantia Nigra of Patients with Parkinson's Disease Related to Their Neuromelanin Content? J. Neurochem. 1992, 59, 1080-1089.
12. Mann, D. M. A.; Yates, P. O. Possible Role of Neuromelanin in the Pathogenesis of Parkinson's Disease. Mech. Ageing Dev. 1983, 21, 193-203.
13. Zhang, F.; Dryhurst, G. Effects of L-Cysteine on the Oxidation Chemistry of Dopamine: New Reaction Pathways of Potential Relevance to Idiopathic Parkinson's Disease. J. Med. Chem. 1994, 37, 1084-1098.
14. Orlowski, M.; Meister, A. The γ-Glutamyl Cycle. A Possible Transport System for Amino Acids. Proc. Nat. Acad. Sci. U.S.A. 1979, 67, 1248-1255.
15. Meister, A. Glutathione: Metabolism and Function via the γ-Glutamyl Cycle. Life Sci. 1974, 15, 177-190.
16. Slivka, A.; Mytilineou, C.; Cohen, G. Histochemical Evaluation of Glutathione in Brain. Brain Res. 1987, 409, 275-284.
17. Carstam, R.; Brinck, C.; Hindemith-Augustsson, A.; Rorsman, H.; Rosengren, E. The Neuromelanin of the Human Substantia Nigra. Biochim. Biophys. Acta 1991, 1097, 152-160.
18. Scatton, B.; Javoy-Agid, F.; Rouquier, L.; Dubois, B.; Agid, Y. Reduction in Cortical Dopamine, Noradrenaline, Serotonin and Their Metabolites in Parkinson's Disease. Brain Res. 1983, 275, 321-328.
19. Farley, I. J.; Hornykiewicz, O. Noradrenaline in Subcortical Brain Regions of Patients with Parkinson's Disease and Control Subjects. In Advances in Parkinsonism; Birkmayer, W., Hornykiewicz, O., Eds.; Editiones Roche: Basel, Switzerland, 1976; pp 178-185.
20. Tse, D. C. S.; McCreery, R. L.; Adams, R. N. Potential Oxidative Pathways of Brain Catecholamines. J. Med. Chem. 1976, 19, 37-40.
21. Marcyniuk, B.; Mann, D. M. A.; Yates, P. O. The Topography of Cell Loss from Locus Coeruleus in Alzheimer's Disease. J. Neurol. Sci. 1986, 76, 335-345.
22. Weinberger, J.; Cohen, G.; Nieves-Rosa, J. Nerve Terminal Damage in Cerebral Ischemia: Greater Susceptibility of Catecholamine Nerve Terminals Relative to Serotonergic Nerve Terminals. Stroke 1983, 14, 986-989.
23. Jenner, P.; Schapira, A. H. V.; Marsden, C. D. New Insights into the Cause of Parkinson's Disease. Neurology 1992, 42, 2241-2250.
24. Hardy, J. A.; Mann, D. M. A.; Wester, P.; Winblad, B. An Integrative Hypothesis Concerning the Pathogenesis and Progression of Alzheimer's Disease. Neurobiol. Ageing 1986, 7, 489-502.
25. Mann, D. M. A. Neuropathological and Neurochemical Aspects of Alzheimer's Disease. In Psychopharmacology of the Aging Nervous System; Iversen, L. L., Iversen, S. D., Snyder, S., Eds.; Plenum Press: New York, 1988; pp 1-67.
26. Hardy, J.; Adolfsson, R.; Alafuzoff, I.; Bucht, G.; Marcusson, J.; Nyberg, P.; Perdahl, E.; Wester, P.; Winblad, B. Transmitter Defecits in Alzheimer's Disease. Neurochem. Int. 1985, 7, 545-563.
27. Smith, C. D.; Carney, J. M.; Starke-Reed, P. E.; Oliver, C. N.; Stadman, E. R.; Floyd, R. A.; Markesbery, W. R. Excess Brain Protein Oxidation and Enzyme Dysfunction in Normal Aging and in Alzheimer's Disease. Proc. Nat. Acad. Sci. U.S.A. 1991, 88, 10540-10543.
28. Subbarao, K. V.; Richardson, J. S.; Ang, L. C. Autopsy Samples of Alzheimer Cortex Show Increased Peroxidation In Vitro. J. Neurochem. 1990, 55, 342-345.
29. Zemlan, F. P.; Thienhaus, O. J.; Bosman, H. B. Superoxide Dismutase Activity in Alzheimer's Disease: A Possible Mechanism for Paired Helical Formation. Brain Res. 1989, 476, 160-162.
30. Pappolla, M. A.; Omar, R. A.; Kim, K. S.; Robakis, N. K. Immunohistochemical Evidence of Antioxidant Stress in Alzheimer's Disease. Am. J. Pathol. 1992, 140, 621-628.
31. Martins, R. N.; Harper, C. G.; Stokes, G. B.; Masters, C. L. Increased Cerebral Glucose-6-Phosphate Dehydrogenase Activity in Alzheimer's Disease May Reflect Oxidative Stress. J. Neurochem. 1986, 46, 1042-1045.
32. Cao, W.; Carney, J. M.; Duchon, A.; Floyd, R. A.; Chevion, M. Oxygen Free Radical Involvement in Ischemia and Reperfusion Injury to the Brain. Neurosci. Lett. 1988, 88, 233-238.
33. Oliver, C. N.; Starke-Reed, P. E.; Stadtman, E. R.; Liu, G. J.; Carney, J. M.; Floyd, R. A. Oxidative Damage to Brain Proteins, Loss of Glutamine Synthetase Activity and Production of Free Radicals During Ischemia/Reperfusion-Induced Injury to Gerbil Brain. Proc. Nat. Acad. Sci. U.S.A. 1990, 87, 5144-5147.
34. Rehncrona, S.; Folbergrová, J.; Smith, D. B.; Siesjö, B. K. Influence of Complete and Pronounced Incomplete Cerebral Ischemia and Subsequent Recirculation on Cortical Concentrations of Oxidized and Reduced Glutathione in the Rat. J. Neurochem. 1980, 34, 477-486.
35. Cooper, J. L.; Pulsinelli, W. A.; Duffy, T. E. Glutathione and Ascorbate During Ischemia and Postischemic Reperfusion in Rat Brain. J. Neurochem. 1980, 35, 1242-1245.
36. Halliwell, B. Reactive Oxygen Species and the Central Nervous System. J. Neurochem. 1992, 59, 1609-1623.
37. Young, T. E.; Babbitt, B. W. Electrochemical Study of the Oxidation of α-Methyldopamine, α-Methylnoradrenaline and Dopamine. J. Org. Chem. 1983, 48, 562-566.
38. Pihel, K.; Schroeder, T. J.; Wightman, R. M. Rapid and Selective Cyclic Voltammetric Measurements of Epinephrine and Norepinephrine as a Method to Measure Secretion from Single Bovine Adrenal Medullary Cells. Anal. Chem. 1994, 66, 4532-4537.
39. Dixon, W. J. The Up - and - Down Method for Small Samples. J. Am. Stat. Assoc. 1965, 60, 967-978.
40. Palumbo, A.; d'Ischia, M.; Misuraca, G.; DeMartino, L.; Prota, G. Iron- and Peroxide-Dependent Conjugation of Dopamine with Cysteine: Oxidative Routes to the Novel Brain Metabolite 5-S-Cysteinyldopamine. Biochim. Biophys. Acta 1995, 1245, 255-261.
41. Shen, X-M.; Dryhurst, G. Further Insights into the Influence of L-Cysteine on the Oxidation Chemistry of Dopamine: Reaction Pathways of Potential Relevance to Parkinson's Disease. Chem. Res. Toxicol. In press.
42. Ma, S.; Lin, L.; Raghavan, R.; Cohenour, P.; Lin, P. Y. T.; Bennett, J.; Lewis, R. J.; Enwall, E.; Kostrzewa, R.; Lehr, R.; Blank, C. L. In Vivo and In Vitro Studies on the Neurotoxic Potential of 6-Hydroxydopamine Analogs. J. Med. Chem. 1995, 38, 4087-4097.
43. Zigmond, M. J.; Hastings, T. G.; Abercrombie, E. D. Neurochemical Responses to 6-Hydroxydopamine and L-DOPA Therapy: Implications for Parkinson's Disease. Ann. N. Y. Acad. Sci. 1992, 648, 71-86.
44. Hirsch, E.; Graybiel, A. M.; Agid, Y. Melanized Dopaminergic Neurons are Differentially Susceptible to Degeneration in Parkinson's Disease. Nature 1988, 334, 345-348.
45. Wrona, M. Z.; Goyal, R. N.; Turk, D. J.; Blank, C. L.; Dryhurst, G. 5,5′-Dihydroxy-4,4′-Bitryptamine: A Potentially Aberrant Neurotoxic Metabolite of Serotonin. J. Neurochem. 1992, 1392-1398.